Figure 1

1. CTL102 (Ad.hCMV-NTR)

2. CTL102/mCMV-mHSP70



3. Ad.mCMV-mHSP70

4. Ad.mCMV-mGM-CSF



Figure 2


A
CTL102/ mCMV-mHSP70
500 100 20
CTL102 extract
HeLa extract
Ad.mCMV-mHSP70
500 100 20
Ad.CMV-LacZ 500
mock
mHSP70
NTR
10 9 8 7 6 5 4 3 2 1
B
Ad.mCMV-mGM-CSF 200
Ad.CMV-LacZ 200
mGM-CSF
2 1

Figure 3


Shaved Area
Ad Infected 4T1 Cells (100µl)
CB1954 (400 mM; 500µl)
Unmodified 4T1 Cells (100µl)
- Opposite Flank -
Days
0
1
2
21
← In vivo Expression of Transgene →
Vaccination
Challenge
• Tumour Incidence
• Tumour Growth
• Survival

Figure 4


A
Vaccinated with 5.0E+4 cells
Vaccinated with 5.0E+3 cells
0 20 40 60 80 100 120
% Naïve Mice Average Tumour Size
B
Vaccinated with 5.0E+4 cells
Vaccinated with 5.0E+3 cells
0 20 40 60 80 100 120
% Naïve Mice Average Tumour Size

Figure 5

A


(a) NTR
(1/6)
(b) NTR-HSP70
(2/6)
Tumour Size (mm²)
Days After tumour challenge
Low Dose Vaccination (5.0E+4)
(c) NTR
(2/5)
(d) NTR-HSP70
(5/6)
(e) Naïve Mice
(0/3)
Days after tumour challenge
High Dose Vaccination (5.0E+5)

Figure 5 (cont.)



Figure 6A


(a) NTR
(2/7)
Tumour Size (mm²)
Days After tumour challenge
(b) NTR + HSP70
(4/7)
Tumour Size (mm²)
Days After tumour challenge
(c) GM-CSF
(3/7)
Tumour Size (mm²)
Days After tumour challenge
(d) NTR + GM-CSF
(4/7)
Tumour Size (mm²)
Days After tumour challenge


(e) Naïve Mice
(0/5)
Tumour Size (mm²)
Days After tumour challenge

Figure 6B


Naive Mice
NTR
GM-CSF
NTR + HSP70
NTR + GM-CSF
Average Tumour Size (mm2)
120
90
60
30
0
0
5
10
15
20
25
Days After tumour challenge